China has recently done much work to encourage novel drug development in the country. Among the efforts is a testing program of market authorization holder scheme (MAH), an optimized approval process for novel drugs and the requirement of clinical data validation, reports The Pharma Letter’s local correspondent Wang Fangquing.
https://www.thepharmaletter.com/article/china-s-push-on-innovation-nourishes-cross-border-collaborations
China’s push on innovation nourishes cross-border collaborations